透明质酸在肿瘤治疗药物新型给药系统中的应用(5)
第1页 |
参见附件。
[17] Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia, 2004,6(4):343-353.
[18] Yamada Y, Hashida M, Hayashi Y, et al. An approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated withhyaluronic acid. J Pharm Sci, 2013 ,102(9):3119-3127.
[19] Surace C, Arpicco S, Dufa-Wojcicki A, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol Pharm, 2009,6(4):1062-1073.
[20] Arpicco S, Lerda C, Dalla Pozza E, et al. Hyaluronic acid-coated liposomes for active targeting of gemcitabine. Eur J Pharm Biopharm, 2013,85(3):373-380.
[21] Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.Cancer Res,,2001,61(6):2592-2601.
[22]Oyarzun-Ampuero FA, Goycoolea FM, Torres D, et al. A new drug nanocarrier consisting of polyarginine and hyaluronic acid. Eur J Pharm Biopharm, 2011,79(1): 54-57.
[23] Kim EJ, Shim G, Kim K, et al.Shim CK. Hyaluronic acid complexed to biodegradable poly-L-arginine for targeted delivery of siRNA. J Gene Med, 2009, 11(9):791-803.
[24] Zhang W, Cheng Q, Guo S, et al. Gene transfection efficacy and biocompatibility of polycation/DNA complexes coated with enzyme degradable PEGylated hyaluronic acid. Biomaterials, 2013, 34(27):6495-6503.
[收稿日期:2014-03-10]
您现在查看是摘要介绍页,详见PDF附件。